Trajtim sipas diagnozës

Gene replacement and gene addition

AAV gene therapy, ex vivo lentiviral stem cell therapy, one-time treatments

Deliver a working copy of the gene, once, and let the child's own cells make the missing protein from then on. The ambition is the highest of any approach here — and so is the irreversibility.

Ku qëndron, gjendje pas gjendjeje

I njëjti trajtim mund të jetë i mbështetur mirë për një problem dhe krejt i paprovuar për një tjetër. Ky është vendi i parë ku familjet çorientohen.

Çfarë është

Two quite different delivery routes share the name, and the difference matters more than families are usually told.

In vivo — a virus shell, almost always an adeno-associated virus (AAV), carries the gene into the child's cells directly. It can be given into a vein, into the spinal fluid, or by neurosurgery into a specific brain region. One administration; nothing is removed from the body.

Ex vivo — the child's own blood stem cells are collected, corrected in a laboratory with a lentiviral vector, and returned. Before they are returned the child needs chemotherapy to clear space in the bone marrow. This is a transplant procedure with a transplant's risks, and it is used for conditions where corrected blood cells can travel into the brain and supply the missing enzyme.

The AAV has a hard size limit, roughly 4.7 thousand letters of DNA. Many of the genes that matter in child neurology — SCN1A, DMD, MECP2 in its regulated form — simply do not fit. This single physical constraint explains most of the creativity in the field: shortened genes, split vectors, and switching on the gene the child already has rather than delivering a new one.

Si pritet të veprojë

The delivered gene mostly does not integrate into the child's chromosomes. It sits in the nucleus as a separate loop and is read from there.

That has an important consequence: in tissues where cells keep dividing, the loop is progressively diluted out. In neurons, which do not divide, it can persist for years. This is why a one-time treatment can be durable in the brain and may not be in the liver or muscle — and why nobody yet knows what happens across a whole human lifetime.

Ex vivo therapy works differently and more permanently: the correction is written into the stem cell's own DNA, so every blood cell it later produces carries it. Some of those cells cross into the brain, mature into microglia, and secrete the missing enzyme for neighbouring cells to take up.

Redosing is usually impossible. The immune system responds to the viral shell, so a second dose of the same vector is likely to be neutralised — and may be dangerous. In practice there is one attempt.

Çfarë është provuar vërtet

• Spinal muscular atrophy again set the standard, and the intrathecal approval in 2025 extended it to children who had been excluded by age or weight.
• The leukodystrophies demonstrated something different: that a blood stem cell transplant carrying a corrected gene can change the course of a brain disease. The same results also showed how narrow the window is — these treatments slow decline in children treated early and do far less once symptoms are established.
• Sanfilippo A in September 2026 is the newest, and worth watching precisely because it is new. A first approval in a condition with no previous treatment is the beginning of the evidence, not the end of it.
• The field has also produced its own cautionary record. Serious liver injury, immune reactions and deaths have occurred with high-dose systemic AAV. Elivaldogene's blood-cancer warning and narrowed indication is the clearest example of a licensed gene therapy whose risk picture changed after approval.

Çfarë nuk dihet

• How long a single dose lasts across a lifetime. The oldest treated children are still young, and nobody can yet say whether a treatment given in infancy still works at thirty.
• Whether redosing will ever be possible, and what it would take to make it safe.
• What happens in children with pre-existing antibodies to the viral shell, who are excluded from most trials and from treatment.
• Whether treating after symptoms appear changes the eventual outcome or only slows the rate of loss.

Rreziqet

• Liver injury with systemic AAV, sometimes severe. Steroid cover before and after dosing is standard, not precautionary, and liver tests are monitored for months.
• Immune reactions to the vector, including complement activation and thrombotic microangiopathy — a labelled risk for the newest products.
• Conditioning chemotherapy before ex vivo therapy, with everything that means in a young child: infection risk, infertility and a small long-term risk of a second cancer.
• Insertional cancers are no longer theoretical: elivaldogene's boxed warning follows real cases of blood cancer in treated boys.
• Neurosurgical risk where delivery is directly into the brain.
• Irreversibility. This is the defining difference from an ASO. If an unwanted effect emerges in year five, there is nothing to stop. Every one of these treatments should come with a structured long-term follow-up plan, and a centre that cannot describe that plan should not be administering it.

Pyetje për të bërë

1. Is this an in vivo infusion or an ex vivo transplant — and if the latter, what conditioning chemotherapy does my child need?
2. Has my child been tested for antibodies to the viral vector?
3. Is there a time window for this gene, and are we inside it?
4. What is the long-term monitoring plan, for how many years, and who runs it?
5. What happens if it does not work, or stops working — is there any second option afterwards?

Metoda të tjera